| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/19/2004 | US20040033994 Use of compounds comprising a nitrogen-oxygen heterocycle |
| 02/19/2004 | US20040033993 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033992 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033991 Treating of cardiovascular and related pathologies |
| 02/19/2004 | US20040033990 Administering mixtures of heterocyclic imines, calcium channel blockers, adrenergic blocking agents, anticoagulants, diuretics and angiotensin converting enzyme inhibitors, for prophylaxis of heart diseases such as arrhythmias or necrosis |
| 02/19/2004 | US20040033989 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033983 Dietetic mixtures comprising polyglucomannans, excipients and lipase inhibitors such as orlistat |
| 02/19/2004 | US20040033981 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| 02/19/2004 | US20040033965 Method for treating obesity |
| 02/19/2004 | US20040033954 Therapeutic method for combined use of modified CNTF and thiadolidinedione |
| 02/19/2004 | US20040033938 Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
| 02/19/2004 | US20040033935 Novel imidazole derivatives, production method thereof and use thereof |
| 02/19/2004 | US20040033932 Myc targets |
| 02/19/2004 | US20040033565 Isolated human G-Protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof |
| 02/19/2004 | US20040033563 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 02/19/2004 | US20040033535 Antibodies to OPGL |
| 02/19/2004 | US20040033527 Methods of using a three-dimensional model of a Fc epsilon receptor alpha chain |
| 02/19/2004 | US20040033526 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
| 02/19/2004 | US20040033520 Diagnosing metastatic colorectal, stomach and/or esophageal cancer in vitro; immunoassay; radioimaging tumors; immunotherapeutics; genetic vaccines |
| 02/19/2004 | US20040033517 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (PAR1) |
| 02/19/2004 | US20040033273 Withania Somnifera plant extracts that at least partially reverse side effects of immunosuppressive radio- or drug therapy and have antitumor activity |
| 02/19/2004 | US20040033268 Hypertonic sodium chloride, a molecule exerting a relaxation effect on vascular smooth muscles, and a molecule able to supply an exogenous phosphate input; treating hypoxia, e.g., neonatal diarrhea and endotoxic shock in ruminants. |
| 02/19/2004 | US20040033267 Nanoparticulate compositions of angiogenesis inhibitors |
| 02/19/2004 | US20040033260 Comprise both chelated and unchelated zinc ions, wherein the quantity of chelated zinc ions is at least 50% |
| 02/19/2004 | US20040033254 Transdermal drug delivery system with improved water absorbability and adhesion properties |
| 02/19/2004 | US20040033253 Transdermal-delivery device |
| 02/19/2004 | US20040033247 Composition in the form of an emulsion that can be used to treat plantar bromhidrosis and/or hyperhidrosis |
| 02/19/2004 | US20040033229 PSMA antibodies and protein multimers |
| 02/19/2004 | US20040033223 Curative and preventive activity in the pathogenesis of thrombo-embolic and haemostatic diseases of arterial or venous origin |
| 02/19/2004 | US20040033210 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
| 02/19/2004 | US20040033208 Antifungal compositions containing an antibiotic and one or more amidoamines |
| 02/19/2004 | US20040033207 Cleansers of soaps, surfactants, detergents, and mixtures, and a soybean derived natural epidermal growth factor receptor inhibitor (egfr) |
| 02/19/2004 | US20040033202 Nanoparticulate sterol formulations and novel sterol combinations |
| 02/19/2004 | US20040033198 Methods for determining effects of maternal treatments on offspring |
| 02/19/2004 | US20040031719 Antihistamine / decongestant regimens for treating rhinitis |
| 02/19/2004 | DE10237423A1 Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound |
| 02/19/2004 | DE10236405A1 New 4-(3-oxo-estra-4,9-dien-11 beta-yl)-benzaldehyde oximes, are progesterone receptor modulators useful in female contraception, hormone replacement therapy and treatment of gynecological disorders |
| 02/19/2004 | CA2495935A1 Screening strategy for anticancer drugs |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2495489A1 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer |
| 02/19/2004 | CA2495103A1 Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases |
| 02/19/2004 | CA2495085A1 Diagnosis and treatment of tuberous sclerosis |
| 02/19/2004 | CA2494911A1 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 02/19/2004 | CA2494865A1 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | CA2494827A1 Cannabinoid receptor ligands |
| 02/19/2004 | CA2494585A1 Methods for the treatment of dementia based on apo e genotype |
| 02/19/2004 | CA2494270A1 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
| 02/19/2004 | CA2494252A1 Psmcs as modifiers of the rb pathway and methods of use |
| 02/19/2004 | CA2494156A1 Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
| 02/19/2004 | CA2494108A1 Amyloid immunization and cox-2 inhibitors for the treatment of alzheimer's disease |
| 02/19/2004 | CA2487399A1 Combination of anti-muscarinic agents and non-glucocorticoid steroids |
| 02/18/2004 | EP1389480A1 Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation |
| 02/18/2004 | EP1389469A1 Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid |
| 02/18/2004 | EP1389468A1 Compositions for promoting healing of bone fracture |
| 02/18/2004 | EP1389467A1 Therapeutic compositions for repairing chondropathy |
| 02/18/2004 | EP1389463A1 Medicine for inhibiting drug elimination pump |
| 02/18/2004 | EP1389306A2 Method for detecting progredient chronic dementia, and corresponding peptides and detection reagents |
| 02/18/2004 | EP1389235A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 02/18/2004 | EP1389205A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
| 02/18/2004 | EP1389131A2 Combinations of a 5ht1 receptor agonist with an analgesic, and an anti-emetic and/or a gastroprokinetic agent |
| 02/18/2004 | EP1389130A2 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 02/18/2004 | EP1389129A1 Methods of treating respiratory conditions |
| 02/18/2004 | EP1389127A1 Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase |
| 02/18/2004 | EP1389122A2 Prevention of epithelial cancer |
| 02/18/2004 | EP1389121A1 Method and compositions for treating mammalian nerve tissue injuries |
| 02/18/2004 | EP1389115A2 As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation |
| 02/18/2004 | EP1389114A2 Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
| 02/18/2004 | EP1389112A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
| 02/18/2004 | EP1389110A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 02/18/2004 | EP1389108A2 Methods for selective immunomodulation using pimecrolimus |
| 02/18/2004 | EP1389106A1 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications |
| 02/18/2004 | EP1389105A1 Method of treatment |
| 02/18/2004 | EP1389099A1 Delivery of beta-blockers through an inhalation route |
| 02/18/2004 | EP1389098A1 Delivery of antipsychotics through an inhalation route |
| 02/18/2004 | EP1389097A1 Delivery of compounds for the treatment of parkinsons through an inhalation route |
| 02/18/2004 | EP1389096A1 Delivery of opioids through an inhalation route |
| 02/18/2004 | EP1389095A1 Delivery of antidepressants through an inhalation route |
| 02/18/2004 | EP1389094A1 Delivery of sedative-hypnotics trough an inhalation route |
| 02/18/2004 | EP1389092A1 Abuse-resistant opioid dosage form |
| 02/18/2004 | EP1389044A1 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation |
| 02/18/2004 | EP1325001B1 Anticholinergic agents that can be used as medicaments and method for the production thereof |
| 02/18/2004 | EP1267932B1 Anti-infective active substance combinations and the use thereof for the topical treatment of fungus diseases of toe and finger nails |
| 02/18/2004 | EP1233786B1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance for the preparation of a medicament |
| 02/18/2004 | EP1216238B1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 02/18/2004 | EP1187635B1 Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist |
| 02/18/2004 | EP1178958B1 N-cyanomethyl amides as protease inhibitors |
| 02/18/2004 | EP1178736B1 A composition containing carvacrol and thymol for use as a bactericide |
| 02/18/2004 | EP1104422B1 Phenyl xanthine derivatives |
| 02/18/2004 | EP0946166B1 Use of matrix metalloproteinase inhibitors for promoting wound healing |
| 02/18/2004 | EP0862462B1 Combination of a beta-receptor blocker and an opioid |
| 02/18/2004 | EP0734264B1 Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| 02/18/2004 | EP0691852B1 Valproic acid covalently bonded to a lysophospholipid |
| 02/18/2004 | CN1476476A Ligand/receptor specificity exchangers that redirect antibodies to receptors on pathogen |
| 02/18/2004 | CN1476448A Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 02/18/2004 | CN1476447A Aminothiazoles and their use as adenosine receptor antagonists |
| 02/18/2004 | CN1476424A 萘衍生物 Naphthalene Derivatives |
| 02/18/2004 | CN1476328A Treatment of osteoporosis |
| 02/18/2004 | CN1476326A Treatment of PCP addiction and PCP addiction-related behavior |
| 02/18/2004 | CN1475498A Preparation of antigen sensitized human dendron shaped cell and its use |